Stock analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN – Get Free Report) in a report issued on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.
OpGen Stock Performance
NASDAQ:OPGN opened at $1.95 on Friday. OpGen has a 1 year low of $1.40 and a 1 year high of $9.90. The stock has a fifty day moving average price of $1.84 and a two-hundred day moving average price of $2.50.
OpGen (NASDAQ:OPGN – Get Free Report) last announced its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter.
About OpGen
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
See Also
- Five stocks we like better than OpGen
- How to Evaluate a Stock Before BuyingÂ
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Upcoming IPO Stock Lockup Period, Explained
- Applied Materials Market Capitulates: Now is the Time to Buy
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.
